

Body Weight/Illness/Clinical scores
Treat
medroxy
HSV-2
Swab/ serum
Swab/ serum
Swab/ serum
Swab/ Serum/DRG
-7
0
7
14
21
28

Fig. 1



A.
Percent survival
100
50
0
0
10
20
30
Time
Group 1
Group 8
Group 9
Group 10
B.
Percent survival
100
50
0
0
10
20
30
Time
Group 2
Group 8
Group 9
Group 10
C.
Percent survival
100
50
0
0
10
20
30
Time
Group 3
Group 8
Group 9
Group 10
D.
Percent survival
100
50
0
0
10
20
30
Time
Group 4
Group 8
Group 9
Group 10
E.
Percent survival
100
50
0
0
10
20
30
Time
Group 5
Group 8
Group 9
Group 10
F.
Percent survival
100
50
0
0
10
20
30
Time
Group 6
Group 8
Group 9
Group 10
G.
Percent survival
100
50
0
0
10
20
30
Time
Group 7
Group 8
Group 9
Group 10

Fig. 2A-2G




Fig. 3



A.
% Original Body Weight
Day post infection
Group 8
Group 9
Group 10
B.
% Original Body Weight
Day post infection
Group 1
Group 8
Group 9
Group 10
C.
% Original Body Weight
Day post infection
Group 2
Group 8
Group 9
Group 10
D.
% Original Body Weight
Day post infection
Group 3
Group 8
Group 9
Group 10
E.
% Original Body Weight
Day post infection
Group 4
Group 8
Group 9
Group 10
F.
% Original Body Weight
Day post infection
Group 5
Group 8
Group 9
Group 10
G.
% Original Body Weight
Day post infection
Group 6
Group 8
Group 9
Group 10
H.
% Original Body Weight
Day post infection
Group 7
Group 8
Group 9
Group 10

Fig. 4A-4H



A
B
C
D
Clinical score
Day post infection
Group 1
Group 2
Group 3
Group 4
Group 8
Group 9
Group 10
0
1
2
3
0
10
20
30

Fig. 5A-5D



A
Clinical score
3
2
1
0
0
10
20
30
Day post infection
Group 5
Group 6
Group 9
Group 10
B
Clinical score
3
2
1
0
0
10
20
30
Day post infection
Group 6
Group 8
Group 9
Group 10
C
Clinical score
3
2
1
0
0
10
20
30
Day post infection
Group 7
Group 8
Group 9
Group 10

Fig. 6A-6C



1.5
1.0
0.5
0.0
vaginal score
0
10
20
30
Day post infection
Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7

Fig. 7



Hair Loss Score
2.0
1.5
1.0
0.5
0.0
0
10
20
30
Day post infection
Group 1
Group 2
Group 3
Hair Loss Score
2.0
1.5
1.0
0.5
0.0
0
10
20
30
Day post infection
Group 4
Group 5
Group 6

Fig. 8



A
B
C
D
Illness score
Day post infection
Group 1
Group 8
Group 9
Group 10
Group 2
Group 3
Group 4
0.0
0.5
1.0
1.5
2.0
2.5
0
10
20
30

Fig. 9A-9D



A
Illness score
2.5
2.0
1.5
1.0
0.5
0.0
0
10
20
30
Day post infection
Group 5
Group 8
Group 9
Group 10
B
Illness score
2.5
2.0
1.5
1.0
0.5
0.0
0
10
20
30
Day post infection
Group 6
Group 8
Group 9
Group 10
C
Illness score
2.5
2.0
1.5
1.0
0.5
0.0
0
10
20
30
Day post infection
Group 7
Group 8
Group 9
Group 10

Fig. 10A-10C



% Original Body Weight
110
100
90
80
0
10
20
30
Day post infection
Group 1
Group 2
Group 5

Fig. 11



Illness score
1.5
1.0
0.5
0.0
-0.5
0
10
20
30
Day post infection
Group 1
Group 2
Group 5

Fig. 12




Group 1
Group 2
Group 5
Clinical score
3
2
1
0
-1
0
10
20
30
Day post infection

Fig. 13

A.



B.





Fig. 14A-14B

A.



B.




Fig. 15A-15B



AUC illness score
60
40
20
0
0
2
4
6
8
10
Fold increase in drug
TD50

Fig. 16



qPCR of Dorsal Root Ganglia
HSV-2 Viral Copy Number/Rxn
0
20
40
60
80
100
120
1
2
3
4
5
6
7
CTL
CTL/trt
Group

Fig. 17



qPCR of Dorsal Root Ganglia
HSV-2 Copy Number/ug DNA
0
200
400
600
800
1000
1200
Mock (N=7)
Treated (N=15)
Untreated (N=4)

Fig. 18



1000000
100000
10000
1000
100
10
Concentration (ng/ml)
0
4
8
12
16
20
24
Time (hr)
Group 1
Group 2
Group 4
Group 5
Group 6
Group 7
Group 8

Fig. 19



1000000
100000
10000
1000
100
10
Concentration (ng/ml)
0
4
8
12
16
20
24
Time (hr)
Group 1
Group 3
Group 4
Group 5
Group 6
Group 7
Group 8

Fig. 20



100000
10000
1000
100
10
Concentration (ng/ml)
0
4
8
12
16
20
24
Time (hr)
Group 1
Group 3
Group 4
Group 5
Group 6
Group 7
Group 8

Fig. 21



500000
400000
300000
200000
100000
0
AUClast (hr•ng/ml)
G1: 125 mg/kg iv
G2: 125 mg/kg po
G4: 32 mg/kg po
G5: 63 mg/kg po
G6: 125 mg/kg po
G7: 250 mg/kg po
G8: 500 mg/kg po

Fig. 22



150000
100000
50000
0
AUClast (hr•ng/ml)
G1: 63 mg/kg iv
G3: 63 mg/kg po
G4: 16 mg/kg po
G5: 32 mg/kg po
G6: 63 mg/kg po
G7: 125 mg/kg po
G8: 250 mg/kg po

Fig. 23





150000
100000
50000
0
AUClast (hr•ng/ml)
G1: 63 mg/kg iv
G3: 63 mg/kg po
G4: 16 mg/kg po
G5: 32 mg/kg po
G6: 63 mg/kg po
G7: 125 mg/kg po
G8: 250 mg/kg po

Fig. 24

A.



B.



C.




Fig. 25A-25C